SKYE BIOSCIENCE INC (SKYE) Stock News
NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD
SKYE Latest News and Analysis
Tuesday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Skye Bioscience Announces Participation in February Conferences
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Provides 2025 Look Ahead and Year in Review
Expected Phase 2 obesity data in Q2 2025 and Q4 2025 will shape clinical potential and development path of distinctive CB1 inhibitor...
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company...
Skye Bioscience to Announce Third Quarter 2024 Results
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
MarketBeat Week in Review – 10/7 - 10/11
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab...
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3...
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea...
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the...
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
Renowned clinicians and academics bring extensive experience in obesity and metabolic medicine...
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors...
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (